MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.
Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and appointed KPMG LLP as the Company’s auditors for the current fiscal year. All candidates proposed for the position of director were elected in the following proportion:
FOR | % FOR | ABSTENTION | % ABSTENTION | |||||
Joseph Arena | 22,405,047 | 93.09 | % | 1,663,754 | 6.91 | % | ||
Frank Holler | 21,008,601 | 87.29 | % | 3,060,200 | 12.71 | % | ||
Paul Lévesque | 20,966,427 | 87.11 | % | 3,102,374 | 12.89 | % | ||
Andrew Molson | 21,067,050 | 87.53 | % | 3,001,751 | 12.47 | % | ||
Dawn Svoronos | 20,964,213 | 87.10 | % | 3,104,588 | 2.90 | % | ||
Elina Tea | 21,734,254 | 90.30 | % | 2,334,547 | 9.70 | % | ||
Dale Weil | 21,009,681 | 87.29 | % | 3,059,120 | 12.71 | % | ||
Jordan Zwick | 23,107,383 | 96.01 | % | 961,418 | 3.99 | % |
Frank Holler will now act as Chair of the Board of Directors of the Company.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-514-336-7800
Last Trade: | US$3.25 |
Daily Change: | 0.01 0.31 |
Daily Volume: | 973,450 |
Market Cap: | US$149.440M |
July 02, 2025 April 09, 2025 April 08, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load